FDA clears Myovant’s relugolix for uterine fibroids, setting up AbbVie clashMyovant has chalked up a second approval for its flagship drug relugolix from the FDA, becoming the first Share XFDA clears Myovant’s relugolix for uterine fibroids, setting up AbbVie clashhttps://pharmaphorum.com/news/fda-clears-myovants-relugolix-for-uterine-fibroids-setting-up-abbvie-clash/
AbbVie’s elagolix shows promise in uterine fibroids treatmentAbbVie’s elagolix has shown promise in a phase 2 trial in women with uterine fibroids, a second indication for Share XAbbVie’s elagolix shows promise in uterine fibroids treatmenthttps://pharmaphorum.com/news/abbvies-elagloix-shows-promise-uterine-fibroids-treatment/
